Notice of Annual General Meeting of Abliva AB (publ)
The shareholders of Abliva AB (publ), corporate identity number 556595-6538, are hereby convened to the Annual General Meeting on Thursday 20 May 2021.
Notice of Extraordinary General Meeting of Abliva AB (publ)
The shareholders of Abliva AB (publ), 556595-6538, are hereby convened to the Extraordinary General Meeting (“EGM”) to be held on Thursday 29 April 2021.
Abliva has completed a directed new issue
Abliva AB (Nasdaq Stockholm: ABLI) (“Abliva” or “the Company”), a biopharmaceutical company in the clinical phase that develops drugs for the treatment of rare and serious primary mitochondrial diseas ...
Abliva investigates the prerequisites for carrying out a directed new issue
Abliva AB (Nasdaq Stockholm: ABLI) (“Abliva” or the “Company”) a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases, toda ...
Abliva AB Year-End Report January – December 2020
2020 summary
Abliva appoints Ellen Donnelly as new CEO as it enters a new stage in its development
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announced that the Board ...
Abliva AB Interim Report January – September 2020
KL1333 is on its way to pivotal clinical study - Pivotal study planned for the second half of 2021
Magnus Persson leaves the Board of Directors of Abliva AB to focus on role as founding partner at Eir Ventures
Abliva AB (Nasdaq Stockholm: ABLI) today announces that Magnus Persson is leaving the company's Board of Directors at his own request, to focus on his role as founding Partner at Eir Ventures, a recen ...
Abliva intends to start a pivotal KL1333 study second half 2021
Abliva AB (Nasdaq Stockholm: ABLI) today announced that the company’s Board of Directors has decided to accelerate the KL1333 clinical program, with the intention to start a pivotal Phase II/III clini ...
Abliva AB Interim Report January – June 2020
NeuroVive Pharmaceutical AB changes its name to Abliva AB - Two share issues bring a total of MSEK 87 to Abliva - Hadean Ventures new strategic owner
Amended number of shares and votes in Abliva AB (publ)
Abliva AB (Nasdaq Stockholm: ABLI), today announced an increase of the number of shares and votes in the company of 26,666,666 as a result of a performed directed rights issue, resolved by the Board o ...
Abliva completes the directed issue of MSEK 20 to Hadean Ventures
On April 22, 2020, the Board of Directors of Abliva AB (publ) ("Abliva" or the "Company") resolved, supported by the authorization granted at the Annual General Meeting on April 25, 2019, on a directe ...